OpenAI has met with officials from the U.S. Food and Drug Administration to discuss the agency's use of AI to speed up drug evaluations, Wired reported on Wednesday. According to the report, OpenAI and the FDA have discussed a project called cderGPT, which seems to be an AI tool for the Center for Drug Evaluation (CDE). The CDE regulates over-the-counter and prescription drugs in the U.S. Associates from Elon Musk's DOGE have reportedly been part of the talks as well. It's not uncommon for drug
Jim Cramer Favors Lam Research Over Applied Materials (AMAT)
We recently published a list of Jim Cramer Talked About These 7 Stocks Recently. In this article, we are going to take a look at where Applied Materials, Inc. (NASDAQ:AMAT) stands against other stocks that Jim Cramer discussed recently. On Monday, Jim Cramer, host of Mad Money, shared valuable insights from his years of experience […]
Insider Monkey
•
9 hours ago
